Raymond James & Associates’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.24M | Sell |
142,108
-21,300
| -13% | -$185K | ﹤0.01% | 2544 |
|
|
2024
Q2 | $1.12M | Sell |
163,408
-31,625
| -16% | -$216K | ﹤0.01% | 2538 |
|
|
2024
Q1 | $1.77M | Buy |
195,033
+66,021
| +51% | +$601K | ﹤0.01% | 2232 |
|
|
2023
Q4 | $575K | Buy |
129,012
+8,451
| +7% | +$37.7K | ﹤0.01% | 2852 |
|
|
2023
Q3 | $379K | Buy |
120,561
+73,324
| +155% | +$230K | ﹤0.01% | 3035 |
|
|
2023
Q2 | $244K | Sell |
47,237
-1,820
| -4% | -$9.39K | ﹤0.01% | 3343 |
|
|
2023
Q1 | $259K | Buy |
49,057
+10,587
| +28% | +$55.8K | ﹤0.01% | 3306 |
|
|
2022
Q4 | $108K | Sell |
38,470
-18,955
| -33% | -$53.3K | ﹤0.01% | 3586 |
|
|
2022
Q3 | $238K | Buy |
57,425
+5,748
| +11% | +$23.8K | ﹤0.01% | 3309 |
|
|
2022
Q2 | $208K | Sell |
51,677
-2,422
| -4% | -$9.75K | ﹤0.01% | 3462 |
|
|
2022
Q1 | $268K | Buy |
54,099
+246
| +0.5% | +$1.22K | ﹤0.01% | 3456 |
|
|
2021
Q4 | $375K | Sell |
53,853
-39,898
| -43% | -$278K | ﹤0.01% | 3286 |
|
|
2021
Q3 | $938K | Buy |
93,751
+29,818
| +47% | +$298K | ﹤0.01% | 2615 |
|
|
2021
Q2 | $907K | Buy |
63,933
+4,279
| +7% | +$60.7K | ﹤0.01% | 2649 |
|
|
2021
Q1 | $979K | Buy |
59,654
+1,610
| +3% | +$26.4K | ﹤0.01% | 2525 |
|
|
2020
Q4 | $1.2M | Sell |
58,044
-35,341
| -38% | -$732K | ﹤0.01% | 2210 |
|
|
2020
Q3 | $711K | Buy |
93,385
+2,855
| +3% | +$21.7K | ﹤0.01% | 2379 |
|
|
2020
Q2 | $754K | Buy |
90,530
+26,855
| +42% | +$224K | ﹤0.01% | 2325 |
|
|
2020
Q1 | $315K | Buy |
+63,675
| New | +$315K | ﹤0.01% | 2722 |
|